Alzheimer's disease (AD) is the most common neurodegenerative disease affecting 27 the elderly worldwide. Mitochondrial dysfunction has been proposed as a key event in 28 the etiology of AD. We have previously modeled amyloid-beta (Aβ)-induced 29 mitochondrial dysfunction in a transgenic Caenorhabditis elegans strain by 30 expressing human Aβ peptide specifically in neurons (GRU102). Here, we focus on a 31 deeper analysis of these metabolic changes associated with A-induced mitochondrial 32 dysfunction. Integrating metabolomics, transcriptomics, biochemical studies and 33 computational modeling, we identify alterations in Tricarboxylic Acid (TCA) cycle 34 metabolism following even low-level Aβ expression. In particular, GRU102 show 35 reduced activity of a rate-limiting TCA cycle enzyme, alpha-ketoglutarate 36 dehydrogenase. These defects are associated with elevation of protein carbonyl 37 content specifically in mitochondria. Importantly, metabolic failure occurs before any 38 significant increase in global protein aggregate is detectable. Treatment with an anti-39 diabetes drug, Metformin, reverses A-induced metabolic defects, reduces protein 40 aggregation and normalizes the lifespan of GRU102. Our results point to metabolic 41 dysfunction as an early and causative event in AD pathology and a promising target 42 for intervention. 43 44 45 46 47 48 49 50 51 Introduction 52
To study the temporal sequence of events underlying A-mediated toxicity, especially 101 the early events affecting mitochondrial metabolism, we have created a novel 102 transgenic C. elegans strain with constitutive pan-neuronal expression of low-levels 103 of human A 1-42 (GRU102) 33 . Similar to previous transgenic strains expressing A in 104 neurons, GRU102 display comparatively mild phenotypes including failure in 105 chemotaxis, with neuromuscular and behavioral defects that become more 106 pronounced with age. Remarkably, even though A aggregates were detectable only 107 in old GRU102 (day 12), we found defects in energy metabolism and significantly 108 reduced activity in mitochondrial electron transport chain (ETC) complexes in 109 GRU102 already when young 33 . Our findings suggest that metabolic alterations are 110 early events in AD pathogenesis, and this prompted us to further investigate why and shown that antioxidant treatment, using the mitochondrial-targeted antioxidant 118
MitoQ, was able to ameliorate depletion of the mitochondrial lipid cardiolipin and 119 improved the healthspan of another strain of transgenic AD nematodes with muscular 120 expression of A (CL2006) 35 . Treatment using an antidiabetic drug, Metformin, has 121 also recently been shown to delay A-related paralysis, and improve neuronal 122 transmission, in two transgenic AD strains, one with inducible muscular (CL4176) 123 and one with neuronal A expression (CL2355) 36 . However, the mechanisms 124 underlying the beneficial AD effects of such metabolism-related drugs are still not 125 fully understood. 126 127 Here we examine how A causes mitochondrial failure in AD, the mechanisms 128 underlying the beneficial effects of Metformin, the metabolic consequences 129 underlying A expression and how they relate to protein aggregation in the GRU102 130 strain. We link A expression to Tricarboxylic acid (TCA) cycle impairment and 131 oxidative protein damage specifically in the mitochondria starting early in life (day 4). 132
These changes occur in the absence of any detectable A aggregates and also precede 133 general protein aggregation as the latter only occurs late in life (day 12), suggesting 134 the disruption in proteostasis is a secondary event likely induced by the early 135 metabolic dysfunction. Metformin treatment normalized lifespan to that of untreated 136 non-transgenic controls, increased stress resistance, reversed metabolic defects and 137 prevented the increase in levels of protein aggregation in GRU102, suggesting that 138 improvement in metabolism can directly enhance proteostasis. Our results, taken 139 together with other recent findings, suggest that disruption in mitochondrial function 140 and redox homeostasis can induce protein aggregation, and targeting these processes 141 can be beneficial in AD [37] [38] [39] [40] .  142   143   144  145  146  147 Results 148
Alterations in amino acid and Tricarboxylic acid cycle metabolism in GRU102 149
GRU102 suffer from early and significant defects in energy metabolism 33 . To 150 determine which energy substrates were specifically affected in GRU102, we 151 followed a targeted metabolomics approach, comparing intermediary metabolites 152 involved in energy production between age-matched GRU102 and its transgenic 153 controls (GRU101). We specifically determined levels of different Acylcarnitines 154 (AC), Triacylglycerides (TAG), amino acids (AA) as well as of organic acids (OA), 155
including TCA cycle intermediates. 156 157 AC are intermediates that are typically generated during the transport of activated 158 long-chain FA from the cytosol to mitochondria for FA oxidation 41 . Even though 159 most AC species are derived from FA, some AC species are formed through non-FA 160
intermediates. For example, Propionylcarnitine (C3) and Isovalerylcarnitine (C5) are 161 derived from the degradation of branched-chain AA while Acetylcarnitine (C2) is a 162 common energy precursor derived from glucose and FA metabolism 41,42 . We found 163 that levels of the common energy precursor C2 were significantly reduced in old 164 GRU102 compared to age-matched GRU101 controls ( Fig 1A) , reflecting a low 165 energy status in old GRU102. AA-derived AC species (C3-and C5-carnitine) were 166 also significantly reduced in old GRU102 ( Fig 1A) , suggesting that AA metabolism 167 was affected in old GRU102. By contrast, FA-derived AC species remained 168 unchanged ( Fig 1A) , suggesting that FA metabolism remained intact even in old 169 GRU102. These findings agree with the observation that levels of storage lipids, 170
Triacylglycerides (TAGs), between GRU102 and GRU101 remained similar ( Fig 1B) 171 while lower total AA levels were observed in old GRU102 ( Fig 1C) . 172 converted into pyruvate, alpha-ketoglutarate (aKG), succinyl CoA, fumarate or 175 oxaloacetate, which can then participate in the TCA cycle 43 ( Fig S1) . To determine 176
how changes in the AA profile of GRU102 relate to metabolic alterations, we 177 classified individual AA by the glucogenic substrate that can be formed from them 178 (oxaloacetate, pyruvate, aKG and succinyl CoA). This analysis of the AA profile 179 demonstrated that, in comparison to age-matched controls, the percentage of 180 glucogenic AA forming pyruvate was significantly reduced in both young and old 181 GRU102 animals, while at the same time, the percentage of AA forming alpha-182 Ketoglutarate (aKG) was significantly increased in both young and old GRU102 183 animals ( Fig 1D) . Given the concurrent reduction in glucose metabolism observed in 184 GRU102, the reduction in glucogenic AA forming pyruvate suggests compensation of 185 pyruvate levels by alternative metabolism from AA. Such changes might be expected 186 to result in concomitant changes in TCA intermediates. 187
188
From the OA profiles, we found only an insignificant trend towards lower pyruvate 189 levels and higher aKG levels in old GRU102 compared to GRU101 ( Fig 1E) . 190
However, both of the TCA cycle intermediates, fumarate and malate, were 191 significantly reduced in old GRU102 ( Fig 1E) . These observations suggest a specific 192 disruption in the TCA cycle that affects some but not all of the TCA intermediates. 193 concentration of GRU101 and GRU102. All values were normalized to respective 198 protein concentration and then to young GRU101 (Two-way ANOVA Dunnett's 199 multiple comparisons test, P<0.05, *; P<0.005, **; P<0.001, ***; n=3 repeats per 200 condition, with approximately 3000 animals per repeat collected from independent 201 cohort). Similar results have been confirmed in one other independent trial. 202 203 204
Reduced alpha-Ketoglutarate Dehydrogenase activity in GRU102 205
To help identify which reaction(s) in and around the TCA cycle were most strongly 206 altered in GRU102, we next performed a computational metabolic flux balance 207 analysis (FBA) using transcriptomics and metabolic data from young GRU101 and 208 GRU102 animals as constraints. Modelling took into consideration gene expression 209 data (RNAseq) and data related to nutritional uptake and metabolic rate, specifically 210 pharyngeal pumping, oxygen consumption, and body size (Table S1 ). Gene 211 expression data were used to curate C. elegans condition-specific metabolic networks 212 by modifying a genome-scale metabolic model of C. elegans (iCEL 1273) 44 using 213 the Gene Inactivity Moderated by Metabolism and Expression (GIMME) algorithm 45 . 214
Specifically, we performed parsimonious flux balance analysis (pFBA 44 ) using the 215 COnstraint-Based Reconstruction and Analysis (COBRA) toolbox 46 to determine the 216 metabolic flux distribution corresponding to maximum biomass production (growth 217 and storage 44 ). We subsequently carried out flux variability analysis (FVA) to 218 determine the range of flux values for individual reactions that maintains the same 219 optimal biomass production for GRU101 and GRU102 (for more details on the flux 220 analysis see Methods), with the aim of identifying reactions and metabolites central to 221 the metabolic alterations in GRU102. 222
223
Comparing the metabolic flux distributions between young GRU101 and GRU102, 224 the FBA suggested a more than two-fold flux changes in several reactions related to 225 aKG, including a ~3-fold reduced production of cytosolic aKG from glutamate and a 226 ~10-fold increased production of cytosolic aKG from 3phosphohydroxypyruvate. We 227 further observed a reversal in the direction of flux in the alanine-pyruvate cycle, 228
where, in young GRU101, alanine and aKG are converted to pyruvate and glutamate, 229 but in GRU102, pyruvate and glutamate are converted to alanine and aKG ( Fig S1) . 230
Scanning through all results of FVA, we identified eight reactions that exhibit such 231 directional inconsistency, defined as reactions where the flux intervals did not have 232 consistent signs (direction) when comparing between GRU101 and GRU102. Seven 233 out of these eight reactions were involved in transport, exchange, and co-factor (ADP, 234 NADH) production, while the remaining reaction participates in the alanine-pyruvate 235 cycle (Table S2 ). Taken together, the pFBA and FVA results motivated us to 236 investigate alterations specifically in the metabolism of aKG as a potential node 237 involved in the metabolic defects of GRU102. the brain of AD patients 48 . Based on the metabolomics and flux analysis, we therefore 247 directly examined the enzymatic activity of LDH, aKGDH, SCS and MDH. We 248 evaluated the maximum rate for LDH, aKGDH, SCS and MDH in extracts of purified 249 mitochondria derived from age-matched GRU102 or GRU101 controls. Out of these 250 four enzymes, we found a significant change (reduction) only in the activity of 251 aKGDH ( Fig 2B for To examine if the reduction in aKGDH activity alone was able to recapitulate the 275 metabolic deficits observed in GRU102, we next exposed GRU101 and GRU102 276 animals to RNAi against the C. elegans aKGDH gene (ogdh-1) and investigated their 277 effects on metabolism using a Seahorse bioanalyzer. To avoid confounding 278 developmental effects, we initiated aKGDH knockdown via RNAi treatment only 279 from adulthood (day 3) in both backgrounds. We found that aKGDH knockdown 280 significantly reduced both basal and maximal respiration in GRU101, an effect 281 similar to the defects in GRU102 ( Fig 2C) . Notably, as for GRU102, the response to 282 the addition of chemical uncoupler appeared both delayed and blunted in GRU101 283 subject to adult aKGDH knockdown. In fact, the oxygen consumption rate (OCR) 284 profile of GRU101 with aKGDH knockdown closely mirrored that of GRU102 (Fig  285   2C ). To evaluate if loss of aKGDH might be a compensatory mechanism, we also 286 carried out lifespan studies in GRU102 subject to RNAi knockdown of aKGDH but 287 found that further loss of this enzyme did not significantly affect lifespan, suggesting 288 that reduced aKGDH activity is not protective in GRU102 ( Fig S3) . We also 289 evaluated metabolic effects of aKGDH knockdown in GRU102 and found that loss of 290 aKGDH, similarly, did not normalize but instead significantly worsened the metabolic 291 flux in GRU102 animals ( Fig 2C) , further confirming that reduction in aKGDH is 292 detrimental in AD. 293
294
Comparing OCR profiles between GRU101 animals subject to aKGDH knockdown 295 and GRU102, we noticed that their timeseries of OCR values following addition of 296 the uncoupler (FCCP) appeared to be similar. To further assess how well the OCR 297 profile of GRU101 fed with aKGDH RNAi correlates with GRU102, we plotted a 298 scatter diagram of OCR of GRU102 vs GRU101 fed with aKGDH RNAi or EV just 299 before and during uncoupling (time measurement 6-12 of Fig2C, after addition of 300 FCCP uncoupler). The correlation coefficient, r, can be used to evaluate how well the 301 respective conditions correlate with each other, with r value close to 1 being 302 indicating a high degree of correlation. We found that the OCR during uncoupling of 303 GRU102 correlates well with that of GRU101 fed with aKGDH RNAi (r=0.98, 304 P<0.001) but not for animals fed EV (r=0.33, P=ns, Fig 2D) , illustrating that aKGDH 305 knockdown causes GRU101 to experience deficits in the response to uncoupling that 306 resembles GRU102. One way in which the OCR time course of GRU101 with 307 aKGDH knockdown resembles GRU102 is an increase in the time taken to reach 308 maximal uncoupled respiration (state 3u), following addition of FCCP. To directly 309 quantify this effect, we compared the time required for OCR values to rise to at least 310 two standard deviation above the average coupled (basal) respiration of the same 311 sample, finding that, while GRU101 rapidly responded to addition of FCCP, both 312 GRU102 and GRU101 subject to aKGDH knockdown suffer significant delays in this 313 response ( Fig 2E) . Interestingly, aKGDH knockdown did not further delay uncoupled 314 respiration in GRU102. Together, these results suggest that aKGDH knockdown is 315 sufficient to recapitulate key metabolic deficits seen in GRU102. 316
Oxidative stress as a potential cause of mitochondrial dysfunction in the 318

GRU102 animals 319
aKGDH has been reported to be sensitive to inactivation by damage mediated by 320 reactive oxygen species (ROS), in part through the oxidation of lipoic acid bound 321 covalently to the E2 subunit of aKGDH 49 . Oxidative stress is thought to contribute to 322 the pathophysiology of AD 21,50 and A has been reported to directly promote 323 oxidative stress 51,52 . ROS-related oxidative damage might therefore be a plausible 324 cause of mitochondrial dysfunction in AD, including aKGDH inactivation. 325
326
Protein carbonylation is one consequence of oxidative damage to protein and protein 327 carbonyl content (PCC) is routinely used to assess ROS-related protein oxidation 53 . 328
To test if oxidative damage to protein might be a plausible cause for the enzymatic 329 and metabolic defects in GRU102, we next determined PCC in whole lysate and in 330 mitochondrial fractions of age-matched GRU102 and GRU101 controls. While total 331 PCC in whole body worm lysate was unchanged in GRU102 ( Fig 3A) , we found a 332 significant elevation in mitochondrial protein carbonyls (mtPCC) even in young 333 GRU102 when compared to GRU101 ( Fig 3B) . These data suggested that ROS-334 mediated damage, specifically within the mitochondrial compartment, is an early 335 pathogenic event occurring in GRU102. 
Metformin improved A pathology in GRU102 349
Given evidence for early disruption in energy metabolism and ROS-mediated damage 350 in GRU102, we next examined whether Metformin, an anti-diabetic drug and 351 metabolic modulator that has been shown previously to improve stress resistance and 352 increase TCA cycle metabolism in Wildtype (WT) C. elegans 54,55 , was able to rescue 353 AD pathology in GRU102. We found that Metformin at a dose of 50mM rescued the 354 lifespan deficit of GRU102 by normalizing its median lifespan to that of untreated 355 GRU101 ( Fig 4A) . Metformin treatment also strengthened stress defense of GRU102, 356 as seen in the reduced in percentage of dead GRU102 following challenge with 357 Paraquat (Fig 4B) , a herbicide that induces superoxide production 56 . While old 358 GRU102 exhibited significantly impaired respiratory capacity, Metformin treatment 359 significantly increased maximal respiratory capacity of GRU102 to a level that was, 360 however, still lower than that of untreated GRU101 ( Fig 4C) . 361
362
To determine which metabolic substrates were involved in this rescue by Metformin, 363
we again performed targeted metabolomic analysis and compared AA, AC and OA 364 intermediates between Metformin treated and untreated old GRU102 (day 12). We 365 found that abundance of almost all AA, except arginine, histidine, ornithine and 366 tyrosine, were significantly increased in Metformin-treated GRU102 ( Fig 4D) . 367
Consistent with the higher AA levels observed, C3-carnitine, which is derived from 368 AA, was also significantly increased in the Metformin-treated GRU102, with levels 369 identical to those in GRU101 ( Fig 4E) . Interestingly, at the same time that it increased 370 AA related metabolites, Metformin treatment significantly reduced the level of fat-371 derived C18:1-carnitine ( Fig 4E) , suggesting that Metformin reduced the amount of 372 energy derived from lipid metabolism relative to that derived from AA metabolism. 373
Metformin treatment also reduced the level of lactate in GRU102 while at the same 374 time increasing the levels of pyruvate, fumarate and malate. Levels of malate were in 375 fact significantly higher than those in GRU101 ( Fig 4F) . Our metabolomics findings 376 were consistent with a previous proteomic analysis of Metformin-treated WT C. 377 elegans, which suggested an enrichment of proteins involved in branched-chain 378 amino acid degradation and TCA cycle metabolism 54 . Collectively, these data suggest 379
that Metformin improves energy substrate availability, and that such metabolic 380 improvement is helpful against A-mediated mitochondrial toxicity in GRU102. Metformin-treated GRU102 (n=6 repeats per condition, with 10 animals per repeat).
394
Similar result has been confirmed in two other independent trials. D) Amino acid, E) 395
Acylcarnitine, F) Organic acid profile of Metformin-treated GRU102. All values were 396 normalized to respective protein level and then to age-matched GRU101 control 397
(unpaired t-test, P<0.05, *; P<0.005, **; n=3 repeats per condition with 398 approximately 3000 animals per repeat collected in three independent cohort). Similar 399 result has been confirmed in one other independent trial. 400 401
402
We next compared the metabolic states of GRU101 and GRU102 animals at different 403 ages (day 4 and 12), together with that of 12 day old Metformin-treated GRU102. The 404
Heatmap of this analysis revealed two distinct clusters of metabolites (Cluster 1 and 405
Cluster 2) that both showed strong age-dependent changes. Metabolites in both 406 clusters significantly declined with age. Metabolites forming Cluster 1 (Isoleucine / 407
Leucine, Methionine, Tyrosine, Isovaleryl Carnitine, Tryptophan, Phenylalanine, 408
Valine, Lactate, Succinate, Hydroxyvaleryl-L-Carnitine and Arginine) showed only 409 minor differences between GRU101 and GRU102. Metformin treatment also had no 410 significant effect on this cluster of metabolites. By contrast, metabolites forming 411
Cluster 2 (Ornithine, aKG, Pyruvate, Histidine, Alanine and Glutamic acid) all 412 showed large differences between GRU101 and GRU102. Metabolites that were part 413 of cluster 2 also declined in abundance with age but their levels were lower in 414 GRU102 at both ages, suggesting a metabolic profile of accelerated metabolic aging 415 in GRU102. Interestingly, Metformin treatment completely normalized the levels of 416 cluster 2 metabolites in old GRU102 to levels at or above those in young GRU101 417 control animals, indicating that Metformin treatment was able to reverse the aging-418 related as well as disease-driven metabolic decline in metabolites of this cluster. 
General protein aggregation as a secondary event to metabolic alterations in AD 435
Increased oxidative stress can disrupt protein homeostasis (proteostasis) through 436 irreversible oxidation and subsequent modifications of proteins, and such damage also 437 impairs protein degradation 57 . Protein degradation, synthesis and quality control, 438 required for turnover of misfolded proteins are all energy-intensive processes making 439 proteostasis an energetically expensive process, dependent on sufficient availability of 440 ATP 58 . Given that we observed increased mtPCC levels and deficits in bioenergetics 441 (ATP) 33 , we next asked whether global proteostasis was affected in the GRU102 442 animals. A disruption of general proteostasis is different from specific formation of 443 A-derived aggregates in that it is expected to affect a wide range of endogenous, 444 aggregation-prone peptides in addition to A peptides. 445
446
To determine whether general protein aggregation occurs in the A-expressing 447 animals, we examined the levels of insoluble proteins via an SDS-page gel method 59 . 448
We found that, when the animals were young, no difference in the levels of insoluble 449 protein was detected between GRU102 and GRU101, indicating that the proteostasis 450 machinery of young GRU102 is still relatively intact (Fig 6A, B) . However, aged 451 GRU102 displayed significantly higher levels of insoluble protein compared to age-452 matched GRU101 (Fig 6A, B) , confirming that proteostasis impairment is a secondary 453 event that occurs late in GRU102, likely as a result of metabolic stress. for all conditions except for old GRU102 with 3 repeats, each repeat contains 462 approximately 1500 animals collected in independent cohort). Similar result has been 463 confirmed in one other trial. 464 465
466
As discussed above, treatment with Metformin results in substantial rescue of 467 metabolic defects in GRU102 animals (Fig 4) . Because metabolic alterations are 468 known to affect proteostasis 37-40 , we next investigated whether metabolic rescue 469 following treatment with Metformin was sufficient to normalize levels of global 470 protein aggregation in aged GRU102. We found that Metformin treatment indeed 471 normalized total levels of insoluble protein in GRU102 to that of GRU101 animals 472 ( Fig 6A, B) . This observation is consistent with the emerging view that metabolic 473 dysregulation and protein aggregation are closely related [37] [38] [39] [40] . neuronal Aβ expression leads to an imbalance between reactive oxygen species (ROS) 480 production and antioxidant (AOX) defense, resulting in oxidative stress as an early 481 event in GRU102. Increase in mitochondrial protein carbonyl content (mtPCC) was 482 also observed as an early phenomenon in GRU102. Elevated oxidative stress further 483 affects ROS-sensitive Tricarboxylic Acid (TCA) cycle enzyme, including alpha-484 ketoglutarate dehydrogenase (aKGDH), resulting in a reduction of its activity as well 485
as altered levels of TCA metabolites (aKGDH, fumarate and malate) in old GRU102.
486
Together with the reduction in electron transfer chain (ETC) complex I and IV 487 activities as well as low ATP levels in the GRU102 animals we reported previously 33 , 488
these phenomena result in metabolic stress. Proteostasis, an energy-intensive process, 489
is impaired by metabolic and oxidative stress, resulting in an increase in general 490 protein aggregates. Treatment with Metformin (Met) increases stress resistance and 491 rescues metabolic defects of GRU102, thereby normalizing the levels of protein 492 aggregates in GRU102. Our study employed GRU102, a strain constitutively expressing low-levels of human 498 A1-42 pan-neuronally. We have previously reported that energy deficits and reduced 499 activities of mitochondrial ETC complexes are early events in GRU102, well before 500 any detectable A aggregates are present 33 . Here, we have shown that key energy 501 substrates, in particular glucogenic AA capable of forming pyruvate and aKG, as well 502 as the TCA cycle intermediates fumarate and malate, are selectively affected in 503 GRU102. Metabolic flux balance analysis, incorporating transcriptomics and 504 metabolic data (oxygen intake and bacterial consumption), suggested alterations in 505 transport or metabolism of aKG to be involved in these defects. Indeed, enzymatic 506 assays of key TCA cycle enzymes confirmed deficiency in a rate-limiting TCA cycle 507 enzyme, aKGDH, involved in aKG metabolism. 508
509
Given that aKGDH is a rate-limiting enzyme in the TCA cycle 60 , reduced aKGDH 510 activity is a plausible explanation for reduced flux through the TCA cycle, lower ATP 511 production and reduced maximum respiratory capacity. Inhibition of aKGDH activity, 512
as observed in GRU102, may therefore partially explain key metabolic defects 513 observed in GRU102. Inactivation of aKGDH may contribute not only to the 514 observed reduction in levels of TCA cycle metabolites downstream of aKG (malate 515 and fumarate), but also explain the general reduction in spare respiratory capacity and 516 energy deficits in the GRU102 animals 23 . To test this hypothesis, we carried out 517 aKGDH RNAi knockdown in adult GRU101 as well as GRU102 animals and found 518 GRU101 fed on aKGDH RNAi suffered metabolic detriments that closely resembles 519 GRU102. Exposure to aKGDH RNAi of GRU102, which are already experiencing 520 reduced aKGDH activity, similarly did not improve their metabolic defects and 521 instead resulted in further detriments ( Fig 2F) . These results suggest that reduction in 522 aKGDH activity is detrimental to metabolic capacity in adults and that it alone can 523 recapitulate the metabolic deficits of AD in C. elegans. Defects in other metabolic 524 enzymes have previously been reported by us and others in C. elegans expressing 525 human Aβ and the data presented here, of course, does not mean that inactivation of 526 aKGDH is the single cause of the metabolic detriments in Aβ1-42-expressing C. 527 elegans 33, 61, 62 . However the observation that loss of aKGDH is able to reproduce 528 several of the metabolic detriments of GRU102 suggests that inactivation of specific 529 enzymes involved in the TCA may be a key mechanism of Aβ toxicity. 530
531
Our study revealed mitochondrial-specific ROS as a potential early cause of 532 mitochondrial dysfunction in our AD model, as shown by the early (day 4) increase in 533 mtPCC but not in global PCC. In vitro experiments have shown that the 534 mitochondrial enzyme aKGDH is particularly sensitive to inactivation by ROS 535 (hydrogen peroxide) 63 , consistent with the involvement of this enzyme in GRU102 536 metabolic defects. Site-specific oxidative modification to mitochondrial but not global 537 protein is one possible mechanism to explain the reduction of aKGDH activity 538 observed in old GRU102. These findings are consistent with other reports showing 539 that mitochondrial enzymes involved in energy regulation are known to be redox 540 sensitive and often inhibited or downregulated in AD 25, 64 . 541
542
Remarkably, we found that metabolic deficits and increased mtPCC were detectable 543 in young GRU102, while increased global protein aggregation was only seen in aged 544
GRU102. This sequence of events suggests that impairment of proteostasis may be 545 late or secondary to metabolic dysfunction and/or to oxidative inactivation of TCA 546 cycle enzymes (Fig 7) . 547
548
Metformin has previously been shown to strengthen stress defense, and to increase 549 branched-chain AA degradation and TCA metabolism in WT C. elegans 54,55 . We 550 found that Metformin treatment normalizes lifespan and mitochondrial function in 551 GRU102 up to the level of untreated GRU101 controls. Lifespan of the Metformin-552 treated GRU102 was even longer than the untreated GRU101. Consistent with 553 previous studies showing that Metformin improves AA and TCA cycle metabolism in 554 WT C. elegans 54 , we demonstrated that Metformin treatment also restores respiratory 555 capacity and improves the availability of glucogenic AA and TCA cycle intermediates 556 in the GRU102 animals. 557 558 Interestingly, we further found that Metformin treatment normalized the level of 559 insoluble protein in GRU102 to that of GRU101 controls, again consistent with the 560 notion that modulating metabolic health can ameliorate proteostasis impairment. 561
However, our results do not preclude the possibility that Metformin improves 562 proteostasis function independently of its action on metabolism. While more work 563 needs to be carried out to confirm the causal relationship between metabolic 564 dysfunction and protein aggregation, our observation is consistent with findings that 565 metabolic health and proteostasis are closely related to each other [37] [38] [39] [40] . 566 567 Given recent reports that Metformin can penetrate through the blood brain barrier 65 , 568 our findings suggest Metformin as an potential therapy for AD. Clinical trials of 569
Metformin in MCI and mild AD patients have already suggested improvement in 570 cognitive function in the Metformin-treated groups 66,67 . However, we noted that the 571 dose of Metformin used in this study (50mM, equivalent to 8.25g/L) is approximately 572 five times higher than the therapeutic concentrations of Metformin reported in human 573 plasma (up to 1.8g/L) 68 . This difference could be due to the low permeability of C. 574 elegans cuticle to exogenous drug compounds, which often leads to the much higher 575 drug concentration needed for therapeutic effects 69 . 
RNA extraction 605
Freshly prepared bacteria (OP50 E. coli) were spotted on 94 cm NGM agar plates on 606 the previous evening and allowed to dry. Synchronized, young adult worms were 607 transferred to fresh plates. For maintaining synchronized populations, FUdR was 608 added to NGMmedia. After two days of treatment with drug or vehicle, adult worms 609 were washed off the plates into 15 ml tubes and then washed several times with fresh 610 buffer until a clear solution was obtained. Clean worm pellets were then frozen and 611 later used for RNA extraction. Total RNA was isolated using Qiagen RNAeasy micro 612 kit (Qiagen, Hilden, Germany) following the standard protocol. The LC run was performed at a flow rate of 0.6 mL min −1 with initial gradient of 664 20%B for 0.5 min, then ramped to 100% B in 2.5 min, maintained for 0.5 min, 665
followed by re-equilibrated the column to the initial run condition (20% B) for 2 min. The mixOmics (6.6.0) R package 76 was used to create the heatmap (Fig 5) using the 677 principal components (PCA) loadings, after scaling and centering, of the raw 678 abundances of each metabolite. 679 680
Metabolic Flux Balance Analysis 681
We employed parsimonious flux balance analysis (pFBA) to evaluate the metabolic 682 reaction fluxes in young GRU101 and GRU102 animals. In pFBA 44 , metabolic fluxes 683 of each metabolites are computed based on the mass balance around every metabolite 684 in the metabolic network under the following assumptions: (1) that the metabolism is 685 operating at steady state (i.e. no change in the metabolite concentrations over time), 686
(2) that the organism/cell optimizes its metabolism according to a biological 687 objective, and (3) that the total absolute flux in the metabolic network is minimized 77 . 688
We performed pFBA using built in functions in the COBRA toolbox 46 in MATLAB. 689
Given the life history of C. elegans, we chose the maximization of biomass 690 production for growth and storage 44 . 691 692 693
We curated condition-specific metabolic network models for the GRU101 and 694 GRU102 animals by pruning the C.elegans genome-scale metabolic model iCEL 695 1273 44 based on strain-specific transcriptomic data, using the Gene Inactivity 696
Moderated by Metabolism and Expression (GIMME) 45 algorithm. Briefly, starting 697 from the genome-scale metabolic network (iCEL 1273) 44 , the algorithm removes 698 reactions whose mRNA transcript levels are below a pre-determined threshold. We 699 set the threshold at the 5 th percentile of the normalized transcript level for each gene. 700
The algorithm then uses flux balance analysis (FBA) to ensure that the reduced model 701 is able to achieve the same optimal biological objective value as the full model. In the 702 event that the resulting model is unable to achieve the same biological objective, 703 GIMME determines the smallest set of previously removed reactions to be added 704 back into the reduced model to replicate the optimal biological objective value of the 705 full model. We confirmed that changing the threshold in the range between 1 and 50 706 percentile does not significantly affect the results of our analysis. 707 708
Using the condition-specific metabolic models for GRU101 and GRU102 animals, we 709 then applied pFBA to determine metabolic fluxes based on the maximization of 710 biomass production. We started by analyzing the metabolic fluxes of the controls 711 (GRU101), using experimentally observed bacterial consumption rate as a constraint 712 on the bacterial intake rate 44,78,79 . We used the results of the pFBA of GRU101 to set 713 constraints on bacterial intake and oxygen consumption rates in the pFBA of 714 GRU102. More specifically, we set the constraint on the bacterial intake rate of 715 GRU102 by scaling the constraint of GRU101 according to the ratio of pharyngeal 716 pumping rates between the two strains. Meanwhile, the oxygen consumption rate of 717 GRU102 is constrained to a scalar multiple of the oxygen consumption rate of 718 GRU101 as determined by pFBA, based on the ratio of experimentally observed 719 oxygen uptake rates between the two strains. 720 721
Flux Variability Analysis and Inconsistent Reactions 722
We performed flux variability analysis (FVA) 80 on the GRU101 and GRU102 723 metabolic models to determine the range (interval) of flux values for each reaction, 724 within which one can vary the flux of a reactionkeeping the others constant -725 without changing the optimal biological objective value. We implemented the FVA 726 using in-built functions in the COBRA toolbox 46 . We compared the results of FVA of 727 GRU101 and GRU102 to identify as inconsistent reactions. Here, a reaction is 728 inconsistent between the two animals when its flux interval according to FVA is 729 located fully to the left (negative) or right (positive) of the origin for at least one of 730 the strains, and the flux intervals between the two animals have values of opposite 731 signs. 732
733
TCA enzyme activity assay 734
Mitochondrial extraction was carried out as described in 81 Protein carbonyl assay was performed as described in 35 . 746 747
Lipidomics analysis 748
Approximately 1500 nematodes per sample were collected, washed with M9 buffer 749 and transferred to 2 mL polypropylene tubes containing 250 µL lysis buffer (20 mM 750
Tris-HCl pH 7.4, 100 mM NaCl, 0.5 mM EDTA, 5% glycerol) and left on ice for 751 15 minutes followed by homogenization using a Bead beater (Precellys, France) 752 maintained at 4 °C. Lipids extraction from the lysed samples was carried out by 753
Folch's extraction. In order to minimize oxidation during and after extraction, 0.5% 754 butylated hydroxytoluene (BHT) was added to the organic solvents. Samples were 755 spiked with known amounts of internal standards (purchased from Avanti polar lipids, 756
Alabaster, AL, USA) corresponding to each lipid class during the extraction to control 757 lipid-class dependent differences in extraction and ionization. Internal standard used 758 for triacylglyceride (TAG) was d5-TAG 48:0. To achieve separation into aqueous and 759 organic phases, the samples were vortexed and centrifuged at 3000 rpm for 5 minutes. 760
The lower phase was then transferred to a fresh centrifuge tube and centrifuged in a 761 vacuum concentrator (SpeedVac, Thermo Savant, Milford, USA) until dry. The dried 762 lipid extract was reconstituted in 50 µL methanol and kept at −80 °C until mass 763 spectrometry analysis. 764 765
Lipidomics mass spectrometric analysis and data processing 766
A 6490 triple Quad Mass spectrometer (QqQ; Agilent, USA) coupled to a 1260-Ultra 767
Performance Liquid chromatography (UPLC) was used for lipid quantification. ESI 768 was used to ionize lipids. Each lipid molecular species was analyzed using a targeted 769 multiple reaction monitoring (MRM) approach containing transitions for known 770 precursor/product mass-to-charge ratio and retention times. The UPLC system was 771 equipped with a Waters ACQUITY BEH C18 column (1.0 × 100 mm) to separate the 772 molecular species using gradient elution. Solvent A was acetonitrile/H 2 O (60:40) with 773 10 mM ammonium formate while solvent B was isopropanol/acetonitrile (90:10) 774 containing 10 mM ammonium formate. The flow rate was 0.4 mL/min and the column 775 temperature 50 °C. Solvent B was set at 70% at injection and increased linearly to 776 100% in 14 minutes, retained at this value for 3 minutes, decreased to 10% in one 777 minute and then retained there until the end of the gradient by 14 minutes. The eluent 778 was directed to the ESI source of the mass spectrometer operated in the positive ion 779 mode. The MS conditions were as follows. For ESI: gas temperature, 250 °C; gas 780 flow, 14 L/minutes; sheath gas temperature, 250 °C; sheath gas flow, 11 L/minutes; 781 and capillary voltage, 3,500 V. 782 LC-MS data obtained on the 6490 QqQ Mass spectrometer were subjected to data 783 processing using MassHunter software (Agilent). The identification of a lipid species 784 was based on mass and retention times (RT). Signal intensities of the targeted species 785 were compared with the intensities from the spiked internal standards and the 786 retention times for the various classes were matched. Data processing, included peak 787 smoothing and integration of areas under the curves for each measured transition. The 788 processed data were exported to excel and normalized to protein content as well as the 789 internal standard. Fold changes were measured by comparison of the different 790 conditions to the control sample and finally the Student's t test was performed to 791 determine whether differences between the samples were statistically significant. 792 (p < 0.05 was considered statistically significant). 793 794
Protein aggregation assay 795
Protein aggregation assay was carried out as described in 59 with some modifications. 796
Worms were collected and washed twice in M9 buffer to remove excess bacteria. On 797 the day of homogenization, worm pellet was re-suspended in RIPA buffer (50mM 798
Tris, 150mM NaCl, 5mM EDTA, 0.5% SDS, 0.5% Sodium Deoxycholate, 1% Triton 799 X-100, 1X Protease inhibitors and 1mM PMSF) and homogenized using a Bead 800
Beater (Benchmark Scientific, Edison, USA). To obtain the detergent-soluble protein, 801 the lysate was removed after the first extraction by centrifugation at 14,000rpm and 802 sequential extraction was done by adding fresh RIPA buffer to the pellet, followed by 803 homogenization in bead beater, and then removing the lysate and repeating this 804 process for another 4 times. This is to ensure that all the soluble protein has been 805 extracted by the detergent in the lysate. To obtain the detergent-insoluble protein, 8M 806
Urea lysis buffer (8M Urea, 1mM DTT, 50mM Tris, 2% SDS, 1x Protease inhibitors 807 and 1x Phosphatase inhibitors) was added to the pellet, vortexed for 10 seconds, 808 centrifuged at 14,000rpm for 10 minutes at room temperature and the lysate was 809 collected. This process was again repeated by adding fresh Urea buffer for 5 times in 810 total. 10ul of lysate from each of the urea extraction was then pooled together to form Metabolic flux assay was conducted using Seahorse Bioanalyzer as described in 82 . 831 832
